This study aims to investigate the dynamics of Angiotensin II Type 1 Receptor Antibodies (AT1R-Ab) before and after kidney transplantation. The purpose is to understand how changes in AT1R-Ab levels may impact post-transplant kidney function and graft survival. Participants will include kidney transplant recipients, and their AT1R-Ab levels will be monitored over a one-year period. This research may help develop better predictive models for transplant outcomes, improving clinical decision-making for transplant physicians.
The study will be conducted as a prospective cohort study involving kidney transplant recipients. The participants will undergo monitoring of their AT1R-Ab levels at multiple time points before and after the transplantation, including 2 weeks, 3 months, and 1 year post-transplant. Data collected will include clinical information such as kidney function tests, graft survival rates, and post-transplant complications. The study will aim to correlate AT1R-Ab dynamics with clinical outcomes such as delayed graft function (DGF), graft loss, and creatinine levels.
Study Type
OBSERVATIONAL
Enrollment
241
Seoul National University Hospital
Seoul, Seoul, South Korea
Biopsy-Proven Acute Rejection (BPAR) within 3 years post-transplant
This study evaluates biopsy-proven acute rejection (BPAR) as the primary outcome, using protocol biopsies at 2 weeks and 1 year post-transplant.
Time frame: Up to 3 years post-transplant
Renal Function: Serum Creatinine and eGFR at 2 weeks, 3 months, and 1 year post-transplant
Secondary outcomes will include renal function, assessed by serum creatinine and eGFR at 2 weeks, 3 months, and 1 year post-transplant. The relationship between AT1R-Ab levels and renal function will be analyzed.
Time frame: At 2 weeks, 3 months, and 1 year post-transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.